Lawmakers are tackling high drug costs with a bill aimed at breaking up powerful pharmacy benefit managers. The blame game unfolds as healthcare players point fingers at each other over skyrocketing prices. Meanwhile, General Motors shifts gears, abandoning its robotaxi business and focusing on smarter vehicles. And, in the holiday spirit, you can chat with an AI Santa Claus thanks to new tech features. It's a mix of fiscal debates and festive fun!
Lawmakers are pushing to regulate pharmacy benefit managers to reduce healthcare costs amid political finger-pointing on budget issues.
GM is pivoting from its robotaxi ambitions to focus on partially automated vehicles due to high development costs and regulatory hurdles.
Deep dives
Fiscal Responsibility and Budget Concerns
The podcast highlights the significant budgetary concerns raised by Treasury Secretary Janet Yellen, who proposed an additional three trillion dollars in deficit reduction over a decade to ensure fiscal sustainability. She emphasizes the lack of action by Congress to address the fiscal challenges, particularly regarding the potential extension of the tax cuts from the 2017 Tax Cuts and Jobs Act, which could exacerbate federal deficits. The discussion notes that both political parties are engaging in narrative strategies to argue the implications of these budgetary decisions, often using complex accounting methods to present their cases. This lack of transparency in budget scoring practices, particularly around a 10-year framework, complicates the understanding of the actual fiscal impact on the country.
Pharmacy Benefit Managers and Healthcare Costs
The issue of pharmacy benefit managers (PBMs) is examined, with a focus on their role in driving up healthcare costs amidst increasing scrutiny from lawmakers. Senators Elizabeth Warren and Josh Hawley are advocating for legislation to prohibit companies from owning both pharmacies and PBMs, arguing that such vertical integration creates conflicts of interest that can hinder price negotiations. The pharmaceutical industry counters this viewpoint, claiming that the proposed regulations would primarily benefit them rather than consumers, potentially leading to higher costs. This ongoing debate illustrates the complex dynamics within the healthcare sector, where multiple stakeholders often shift blame for rising drug prices.
Advancements in Autonomous Vehicle Technology
General Motors has announced a strategic shift in its approach to autonomous vehicle (AV) technology, signaling the end of its robo-taxi aspirations with Cruise. Instead, GM will focus on integrating partially automated features into its vehicles, consolidating efforts from both GM and Cruise engineering teams. This decision is influenced by the astronomical costs associated with developing self-driving technology, which have already reached $10 billion, alongside regulatory challenges and significant public relations hurdles experienced by Cruise. Despite the obstacles, there is an acknowledgment that successful AV technology could ultimately lead to improved safety on the roads.
A group of lawmakers have introduced legislation that would break up health care conglomerates, aiming to rein in the power of pharmacy benefit managers. We’ll explain what PBMs do and why all sides of the health care industry are pointing fingers at one another over high costs. We’ll also get into how the future of the Trump-era tax cuts could impact the federal deficit and why General Motors is ditching its robotaxi business. Plus, now’s your chance to talk with an AI Santa Claus.
Tomorrow is our last episode of the year! Join us for our annual holiday party on “Economics on Tap.” The YouTube livestream starts at 3:30 p.m. Pacific time, 6:30 p.m. Eastern.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
